Ritlecitinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 249 publications
RETRACTION: Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.
Journal: The Journal of dermatology
Published: August 28, 2026
Dupilumab and ritlecitinib combination therapy in a patient with alopecia totalis and atopic disease.
Journal: JAAD case reports
Published: August 08, 2026
Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.
Journal: Journal of drugs in dermatology : JDD
Published: August 05, 2026
Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
Journal: American journal of clinical dermatology
Published: July 28, 2026
Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care.
Journal: Journal of clinical medicine
Published: June 21, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: June 18, 2026
Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study.
Journal: Journal of the American Academy of Dermatology
Published: June 12, 2026
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: May 28, 2026
Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment.
Journal: The Journal of dermatological treatment
Published: May 15, 2026
Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.
Journal: Dermatology and therapy
Published: May 05, 2026
Last Updated: 09/26/2026